VALSARTAN DEXCEL 40

Country: Israel

Language: English

Source: Ministry of Health

Active ingredient:

VALSARTAN

Available from:

DEXCEL PHARMA TECHNOLOGIES LTD

ATC code:

C09CA03

Pharmaceutical form:

FILM COATED TABLETS

Composition:

VALSARTAN 40 MG

Administration route:

PER OS

Prescription type:

Required

Manufactured by:

DEXCEL LTD, ISRAEL

Therapeutic group:

VALSARTAN

Therapeutic area:

VALSARTAN

Therapeutic indications:

Valsartan is indicated for the treatment of heart failure (NYHA class II-IV) in patients who are intolerant of angiotensin converting enzyme inhibitors. In a controlled clinical trial Valsartan significantly reduced hospitalisations for heart failure. There is no evidence that Valsartan provides added benefits when it is used with an adequate dose of an ACE inhibitor. Valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

Authorization date:

2016-12-31

Patient Information leaflet

EACH TABLET CONTAINS Valsartan at a dosage
of 40, 80 or 160 mg respectively.
INACTIVE
INGREDIENTS
AND
ALLERGENS
IN
THE MEDICINE - see section 6 "Additional
information".
READ THIS ENTIRE LEAFLET CAREFULLY BEFORE
YOU START USING THIS MEDICINE. This leaflet
contains
concise
information
about
this
medicine. If you have additional questions,
refer to the doctor or pharmacist.
This
medicine
has
been
prescribed
for
treatment of your illness. Do not pass it on
to others. It may harm them, even if it seems
their illness is the same as yours.
1. WHAT IS THE MEDICINE INTENDED
FOR?
VALSARTAN
DEXCEL
40
is
intended
for
the
treatment
of
heart
failure
and
to
reduce
hospitalizations in patients with intolerance
to angiotensin converting enzyme inhibitors
(ACEi). For treatment following myocardial
infarction, to improve survival.
VALSARTAN DEXCEL 80 AND 160 are intended
for the treatment of hypertension. For the
treatment
of
heart
failure
and
to
reduce
hospitalizations in patients with intolerance
to angiotensin converting enzyme inhibitors
(ACEi). For treatment following myocardial
infarction, to improve survival.
•
Hypertension increases the workload of the
heart and arteries. If the hypertension is not
treated, the blood vessels of the brain, heart
and kidneys could be damaged. The result
may cause a stroke, heart failure or kidney
failure. Hypertension increases the risk of
heart attacks. Lowering blood pressure to
normal levels reduces the risk of developing
these disorders.
•
For the treatment of adult patients following
a
heart
attack
(myocardial
infarction),
in order to improve survival and reduce
additional
heart
problems.
•
For
the
treatment
of
symptomatic
heart
failure
in
adult
patients.
Heart
failure
includes shortness of breath, swelling of
the legs and feet due to fluid build-up. Heart
failure means that the heart muscle cannot
pump blood strongly enough to supply all
the blood needed by the body.
THERAPEUTIC GROUP:
Angiotensin II receptor antagonist.
Valsartan belongs to a class of medicines
that block the an